The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
The global Anti-Venom market was valued at US$ 959.2 million in 2023 and is anticipated to reach US$ 1283.7 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
This report aims to provide a comprehensive presentation of the global market for Anti-Venom, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Venom.
Report Scope
The Anti-Venom market size, estimations, and forecasts are provided in terms of sales volume (K Vials) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Venom market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Venom manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Segment by Application
Non-profit Institutions
Hospitals and Clinic
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-Venom manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-Venom in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
The global Anti-Venom market was valued at US$ 959.2 million in 2023 and is anticipated to reach US$ 1283.7 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
This report aims to provide a comprehensive presentation of the global market for Anti-Venom, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Venom.
Report Scope
The Anti-Venom market size, estimations, and forecasts are provided in terms of sales volume (K Vials) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Venom market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Venom manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Segment by Application
Non-profit Institutions
Hospitals and Clinic
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-Venom manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-Venom in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Anti-Venom Market Overview
1.1 Product Overview and Scope of Anti-Venom
1.2 Anti-Venom Segment by Type
1.2.1 Global Anti-Venom Market Value Comparison by Type (2024-2030)
1.2.2 Polyvalent Anti-Venom
1.2.3 Monovalent Anti-Venom
1.3 Anti-Venom Segment by Application
1.3.1 Global Anti-Venom Market Value by Application: (2024-2030)
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinic
1.4 Global Anti-Venom Market Size Estimates and Forecasts
1.4.1 Global Anti-Venom Revenue 2019-2030
1.4.2 Global Anti-Venom Sales 2019-2030
1.4.3 Global Anti-Venom Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-Venom Market Competition by Manufacturers
2.1 Global Anti-Venom Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-Venom Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-Venom Average Price by Manufacturers (2019-2024)
2.4 Global Anti-Venom Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-Venom, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-Venom, Product Type & Application
2.7 Anti-Venom Market Competitive Situation and Trends
2.7.1 Anti-Venom Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-Venom Players Market Share by Revenue
2.7.3 Global Anti-Venom Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Venom Retrospective Market Scenario by Region
3.1 Global Anti-Venom Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-Venom Global Anti-Venom Sales by Region: 2019-2030
3.2.1 Global Anti-Venom Sales by Region: 2019-2024
3.2.2 Global Anti-Venom Sales by Region: 2025-2030
3.3 Global Anti-Venom Global Anti-Venom Revenue by Region: 2019-2030
3.3.1 Global Anti-Venom Revenue by Region: 2019-2024
3.3.2 Global Anti-Venom Revenue by Region: 2025-2030
3.4 North America Anti-Venom Market Facts & Figures by Country
3.4.1 North America Anti-Venom Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-Venom Sales by Country (2019-2030)
3.4.3 North America Anti-Venom Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Anti-Venom Market Facts & Figures by Country
3.5.1 Europe Anti-Venom Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-Venom Sales by Country (2019-2030)
3.5.3 Europe Anti-Venom Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-Venom Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-Venom Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-Venom Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-Venom Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Anti-Venom Market Facts & Figures by Country
3.7.1 Latin America Anti-Venom Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-Venom Sales by Country (2019-2030)
3.7.3 Latin America Anti-Venom Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-Venom Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-Venom Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-Venom Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-Venom Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-Venom Sales by Type (2019-2030)
4.1.1 Global Anti-Venom Sales by Type (2019-2024)
4.1.2 Global Anti-Venom Sales by Type (2025-2030)
4.1.3 Global Anti-Venom Sales Market Share by Type (2019-2030)
4.2 Global Anti-Venom Revenue by Type (2019-2030)
4.2.1 Global Anti-Venom Revenue by Type (2019-2024)
4.2.2 Global Anti-Venom Revenue by Type (2025-2030)
4.2.3 Global Anti-Venom Revenue Market Share by Type (2019-2030)
4.3 Global Anti-Venom Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-Venom Sales by Application (2019-2030)
5.1.1 Global Anti-Venom Sales by Application (2019-2024)
5.1.2 Global Anti-Venom Sales by Application (2025-2030)
5.1.3 Global Anti-Venom Sales Market Share by Application (2019-2030)
5.2 Global Anti-Venom Revenue by Application (2019-2030)
5.2.1 Global Anti-Venom Revenue by Application (2019-2024)
5.2.2 Global Anti-Venom Revenue by Application (2025-2030)
5.2.3 Global Anti-Venom Revenue Market Share by Application (2019-2030)
5.3 Global Anti-Venom Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL
6.1.1 CSL Corporation Information
6.1.2 CSL Description and Business Overview
6.1.3 CSL Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Anti-Venom Product Portfolio
6.1.5 CSL Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Anti-Venom Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 BTG
6.3.1 BTG Corporation Information
6.3.2 BTG Description and Business Overview
6.3.3 BTG Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BTG Anti-Venom Product Portfolio
6.3.5 BTG Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Anti-Venom Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Haffkine Bio-Pharmaceutical
6.5.1 Haffkine Bio-Pharmaceutical Corporation Information
6.5.2 Haffkine Bio-Pharmaceutical Description and Business Overview
6.5.3 Haffkine Bio-Pharmaceutical Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Haffkine Bio-Pharmaceutical Anti-Venom Product Portfolio
6.5.5 Haffkine Bio-Pharmaceutical Recent Developments/Updates
6.6 Rare Disease Therapeutics
6.6.1 Rare Disease Therapeutics Corporation Information
6.6.2 Rare Disease Therapeutics Description and Business Overview
6.6.3 Rare Disease Therapeutics Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Rare Disease Therapeutics Anti-Venom Product Portfolio
6.6.5 Rare Disease Therapeutics Recent Developments/Updates
6.7 Flynn Pharma
6.6.1 Flynn Pharma Corporation Information
6.6.2 Flynn Pharma Description and Business Overview
6.6.3 Flynn Pharma Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Flynn Pharma Anti-Venom Product Portfolio
6.7.5 Flynn Pharma Recent Developments/Updates
6.8 Vins Bioproducts
6.8.1 Vins Bioproducts Corporation Information
6.8.2 Vins Bioproducts Description and Business Overview
6.8.3 Vins Bioproducts Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Vins Bioproducts Anti-Venom Product Portfolio
6.8.5 Vins Bioproducts Recent Developments/Updates
6.9 Bharat Serums and Vaccines
6.9.1 Bharat Serums and Vaccines Corporation Information
6.9.2 Bharat Serums and Vaccines Description and Business Overview
6.9.3 Bharat Serums and Vaccines Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bharat Serums and Vaccines Anti-Venom Product Portfolio
6.9.5 Bharat Serums and Vaccines Recent Developments/Updates
6.10 Serum Biotech
6.10.1 Serum Biotech Corporation Information
6.10.2 Serum Biotech Description and Business Overview
6.10.3 Serum Biotech Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Serum Biotech Anti-Venom Product Portfolio
6.10.5 Serum Biotech Recent Developments/Updates
6.11 MicroPharm
6.11.1 MicroPharm Corporation Information
6.11.2 MicroPharm Anti-Venom Description and Business Overview
6.11.3 MicroPharm Anti-Venom Sales, Revenue and Gross Margin (2019-2024)
6.11.4 MicroPharm Anti-Venom Product Portfolio
6.11.5 MicroPharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-Venom Industry Chain Analysis
7.2 Anti-Venom Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-Venom Production Mode & Process
7.4 Anti-Venom Sales and Marketing
7.4.1 Anti-Venom Sales Channels
7.4.2 Anti-Venom Distributors
7.5 Anti-Venom Customers
8 Anti-Venom Market Dynamics
8.1 Anti-Venom Industry Trends
8.2 Anti-Venom Market Drivers
8.3 Anti-Venom Market Challenges
8.4 Anti-Venom Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
